Discovery of selective CDK9 degraders with anti-AML activity using PROTAC technology.

Authors

Qing Li, Fuyuan Zhou, Ding Luo, Yan Yang, Tingting Hou, Junyang Chen, Jingsong Yu, Shilong Wu, Mingran Xu, Cheng Zou, Weiwei Xue, Liangjing Xin, Zhi-Peng Wang, Chao Huang

Published in

Bioorganic chemistry. Volume 180. Pages 110091. Jun 12, 2026. Epub Jun 12, 2026.

Abstract

Cyclin-dependent kinase 9 (CDK9) has emerged as a pivotal therapeutic target in oncology, characterized by aberrant overexpression in both hematologic cancers and solid neoplasms. Selective CDK9 inhibition effectively disrupts transcriptional programs in tumor cells and induces apoptosis. Herein, we describe the generation of several proteolysis targeting chimeras (PROTACs) using the CDK9 inhibitor DRB as the core ligand. Compound D6 emerged as the most active degrader in this series, eliciting CDK9 degradation with a D_max value of 45% in acute myeloid leukemia (AML) cells. The cellular activity of D6 was found to be 12 times higher than that of its parental inhibitor DRB, while showing no degradation activity toward other CDK family kinases. This enhanced antiproliferative activity was primarily mediated through increased induction of apoptosis. Furthermore, D6 suppressed tumor growth in vivo, achieving an inhibition rate of 31%, and demonstrated a favorable safety profile. Our findings indicate that D6 is a promising candidate worthy of further investigation, and that CDK9-targeted degradation is a valuable potential therapeutic option for AML.

PMID:
42320115
Bibliographic data and abstract were imported from PubMed on 20 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.